Management of hepatitis C virus genotype 4

被引：20

作者：

Abdo, AA ^{[1
]}

Lee, SS ^{[1
]}

机构：

[1] Univ Calgary, Liver Unit, Calgary, AB, Canada

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2004年 / 19卷 / 11期

关键词：

chronic hepatitis; interferon; pegylated; ribavirin; therapy;

D O I：

10.1111/j.1440-1746.2003.03325.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Hepatitis C virus (HCV) genotype 4 is predominantly found in the Middle East and North Africa. Because most of the large randomized controlled trials of antiviral therapy for chronic hepatitis C were conducted in North America and Europe, little is known about management of patients with this particular genotype. Based on the available data, sustained virological response rates to interferon-based therapies appear to be intermediate between the relatively resistant HCV genotype I and the readily responsive genotypes 2 and 3. Several large prospective studies of pegylated interferon plus ribavirin combination therapy, the current gold-standard treatment, have recently been completed and will be reviewed. (C) 2004 Blackwell Publishing Asia Pry Ltd.

引用

页码：1233 / 1239

页数：7

共 57 条

[1] Hepatitis c virus (HCV) infection in a community in the Nile Delta: Population description and HCV prevalence [J].